Sign In
Buy ATNX
$0.203
+0 (+0%)
At Close: Aug 23, 2023
ATNX Stock Price Fell Over 55% Pre-Market: Why It Happened
08:59am, Monday, 01'st Mar 2021
The stock price of Athenex Inc (NASDAQ: ATNX) fell by over 55% pre-market. This is why it happened.
Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer
07:28am, Monday, 01'st Mar 2021
The FDA has issued a complete response letter (CRL) for Athenex Inc's (NASDAQ: ATNX) marketing application seeking approval for oral paclitaxel plus encequidar to treat metastatic breast cancer.
Athenex Provides Fourth Quarter and Full Year 2020 Corporate and Financial Update
07:05am, Monday, 01'st Mar 2021
BUFFALO, N.Y., March 01, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies fo
Athenex's Earnings Outlook
10:17am, Friday, 26'th Feb 2021
Athenex (NASDAQ:ATNX) announces its next round of earnings this Monday, March 01. Here is Benzinga's everything-that-matters guide for this Monday's Q4 earnings announcement.
Athenex: PDUFA This Week, Depressed Price, Likely Opportunity
05:12pm, Wednesday, 24'th Feb 2021
ATNX won one approval in December and has a PDUFA on Feb 28.
Athenex to Provide a Corporate and Financial Update for the Fourth Quarter and Full Year 2020 on March 1, 2021
07:00am, Monday, 22'nd Feb 2021
BUFFALO, N.Y., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex Launches Klisyri In US For Actinic Keratosis; Expands Tirbanibulin Distribution Pact For Additional Territories
09:24am, Thursday, 18'th Feb 2021
Athenex Inc (NASDAQ: ATNX) has launched Klisyri (tirbanibulin) in the U.S., led by the Company's partner Almirall. The launch has triggered a milestone payment of up to $65 million.
Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin
07:55am, Thursday, 18'th Feb 2021
BUFFALO, N.Y., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
CEO Dr. Johnson Lau Recuperating from COVID at Home
04:05pm, Monday, 25'th Jan 2021
BUFFALO, N.Y., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
CEO Dr. Johnson Lau Contracts COVID-19
04:05pm, Friday, 08'th Jan 2021
BUFFALO, N.Y., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference
04:30pm, Tuesday, 05'th Jan 2021
BUFFALO, N.Y., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
BUFFALO, N.Y., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
08:05am, Tuesday, 17'th Nov 2020
BUFFALO, N.Y., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for
Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update
07:00am, Thursday, 05'th Nov 2020
FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer
Investing $5,000 in These 2 Biotechs Could Make You Rich
07:05am, Sunday, 25'th Oct 2020
These two companies aren't reinventing the wheel, but they still have the potential for tremendous growth.
